Novel Vaccine Reduces Shedding of Genital Herpes Virus
Sexually transmitted infection researchers potentially have reached a milestone in vaccine treatment for genital herpes, according to a report to be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver on Sept. 12.
Kenneth H. Fife, MD, is the principal investigator for the IU School of Medicine clinical study of the vaccine for herpes simplex virus type 2 called GEN-003. According to an interim analysis, the experimental protein subunit vaccine made by Genocea Biosciences of Cambridge, Mass., effectively reduces viral shedding.
"Typically vaccines do not modulate a disease someone already has contracted," says Fife, a professor of medicine and of microbiology and immunology. "The virus can be detected on the skin of people with genital herpes even when they are not having an outbreak. That is often how the disease is spread, often called viral shedding."
The injectable vaccine is given several times over the course of a few weeks. The clinical study is closed to enrollment, but participants continue to be followed. GEN-003 is one of the first vaccines intended to reduce the viral shedding and frequency and severity of outbreaks and transmission of herpes simplex virus type 2, which is the most common cause of genital herpes. It is estimated to infect more than 500 million people worldwide, and one out of six people age 14 to 49. In the U.S., an estimated 50-60 million people are affected.
"Although the ultimate goal of this vaccine is reducing genital herpes outbreaks and reducing transmission of the virus to others, this is only the first step on a long path toward reaching that goal. It will take several more studies and a number of years to determine if we can reach that goal," Fife cautions.
APIC Salutes 2025 Trailblazers in Infection Prevention and Control
June 18th 2025From a lifelong mentor to a rising star, the Association for Professionals in Infection Control and Epidemiology (APIC) honored leaders across the career spectrum at its 2025 Annual Conference in Phoenix, recognizing individuals who enhance patient safety through research, leadership, and daily practice.
Building Infection Prevention Capacity in the Middle East: A 7-Year Certification Success Story
June 17th 2025Despite rapid development, the Middle East faces a critical shortage of certified infection preventionists. A 7-year regional initiative has significantly boosted infection control capacity, increasing the number of certified professionals and elevating patient safety standards across health care settings.
Streamlined IFU Access Boosts Infection Control and Staff Efficiency
June 17th 2025A hospital-wide quality improvement project has transformed how staff access critical manufacturer instructions for use (IFUs), improving infection prevention compliance and saving time through a standardized, user-friendly digital system supported by unit-based training and interdepartmental collaboration.
Swift Isolation Protocol Shields Chicago Children’s Hospital During 2024 Measles Surge
June 17th 2025When Chicago logged its first measles cases linked to crowded migrant shelters last spring, one pediatric hospital moved in hours—not days—to prevent the virus from crossing its threshold. Their playbook offers a ready template for the next communicable-disease crisis.
Back to Basics: Hospital Restores Catheter-Associated UTI Rates to Prepandemic Baseline
June 16th 2025A 758-bed quaternary medical center slashed catheter-associated urinary tract infections (CAUTIs) by 45% over 2 years, proving that disciplined adherence to fundamental prevention steps, not expensive add-ons, can reverse the pandemic-era spike in device-related harm.
